News and Announcements
Article highlight
Australia’s 60,000 Business Succession Crisis: Why Good Companies Will Close Their Doors
The Australian Business Growth Fund identified approximately 162,000 privately held businesses in Australia with revenue between AUD$2 million and AUD$100 million. More than two-thirds are owned by people of retirement age. When surveyed, another two-thirds do not have a succession plan in place. The mathematics are stark. 60,000 businesses owned by someone of retirement age […]
Capital Insights
1
What is a Sophisticated Investor in Australia? 2026 Guide
2
The ‘Banknote’ Blueprint: Halocell’s Plan to Print the Next Solar Revolution
3
The Iron Chaperone: Alterity’s High-Stakes Sprint on Brain Iron Redistribution
4
What is a Wholesale Investor in Australia? Complete 2026 Guide
Executive Interviews
Australia’s 60,000 Business Succession Crisis: Why Good Companies Will Close Their Doors
The Australian Business Growth Fund identified approximately 162,000 privately held businesses in Australia with revenue between AUD$2 million and AUD$100 million. More than two-thirds are owned by people of retirement age. When surveyed, another two-thirds do not have a succession plan in place. The mathematics are stark. 60,000 businesses owned by someone of retirement age […]
The ‘Banknote’ Blueprint: Halocell’s Plan to Print the Next Solar Revolution
Beyond rooftops—Halocell Energy’s “banknote” printing creates highly efficient, flexible, lightweight, recyclable and cost-effective solar cells for shaded areas and from dawn to dusk, detailing the three-horizon plan.
The Iron Chaperone: Alterity’s High-Stakes Sprint on Brain Iron Redistribution
Multiple System Atrophy (MSA) is a devastating neurological disease with no known cure. Alterity Therapeutics is breaking the “black box” of MSA with ATH434, a first-in-class drug that targets toxic iron accumulation. After successful Phase 2 results, the company is now scaling for a pivotal Phase 3 trial, positioning itself as a frontrunner in a multi-billion dollar orphan drug market.
Capital Insights
What is a Sophisticated Investor in Australia? 2026 Guide
A sophisticated investor is an individual who has been certified by a qualified accountant as meeting specific financial thresholds under the Corporations Act 2001 (Cth). This certification allows them to participate in investment opportunities that do not require the full disclosure protections mandated for retail investors, such as a prospectus or Product Disclosure Statement. The […]
What is a Wholesale Investor in Australia? Complete 2026 Guide
What is a Wholesale Investor in Australia? A wholesale investor is an individual or entity that meets specific financial thresholds set out in the Corporations Act 2001 (Cth), qualifying them to access investment opportunities that are not available to general retail investors. These include private equity rounds, venture capital deals, pre-IPO placements, alternative funds, and […]
Why the 20-Year Hold Is the Secret to Australian Life Sciences Returns
Australia represents 0.3% of the world’s population. Yet it generates more than 3% of global research output. Cochlear implants. Wi-Fi. The HPV vaccine. These are not statistical anomalies. They are proof points of a structural advantage that Australia has failed to capitalise on. The country has a world-class research base. But it watches companies scale […]
Company Updates
The Australian Life Science Sector: A Structural Convergence of 5 Critical Factors
For a decade, we have watched the foundation being built. Government grants are flowing into research infrastructure. Labs constructed. IP portfolios are growing. Talent returning from global pharma. For most of that decade, the returns were slow, the timelines were long, and the capital was cautious. That era is over. The Australian life science sector […]
Private Credit Is No Longer Just a Defensive Play. Here Is What Investors Actually Want.
Private credit is no longer just a defensive allocation. Based on our 2026 Investor Survey, the largest segment of investors (44%) now wants hybrid structures that combine yield with equity optionality, demanding that fund managers rethink how credit products are structured, positioned, and sold.
Where Capital Is Flowing in 2026: What Active Investors Told Us About the Sectors That Matter
Every year, we survey our investor network. Not to confirm what we already think, but to understand what is actually driving capital allocation decisions across the sophisticated investor community. This year, the results were striking. Not because they were surprising, but because of how precisely they align with the macro research now emerging from some […]
Forget antibiotics: Why the next big medical breakthrough is a beam of light
Lindo Life Science, founded by Robert Gangi, is changing the battle against antimicrobial resistance (AMR) with the Lindo Tube, which uses occupant-safe antimicrobial blue light to shatter 99.9% of bacteria. This breakthrough prevents Ventilator-Associated Pneumonia (VAP), a secondary infection affecting nearly one in four intubated patients, and has been validated by a collaboration with the Mayo Clinic.
Inside the Australian Life Sciences Boom: Renowned Investors, World-Class Partners, World-Leading Breakthroughs
The Australian life sciences sector is experiencing an unprecedented boom, marked by world-leading partnerships, rapid regulatory progress, and significant capital investment. The Emergence Preview Series showcased companies with technologies already in clinical trials and backed by renowned global institutions and investors. This moment feels different due to the maturity and global reach of Australian life sciences innovation.
The 2026 Family Office Briefing: The Great Professionalisation
The days of the family office as a “cottage industry” are over. As complexity overtakes capital, ultra-wealthy families are rapidly professionalising, shifting their focus to direct private markets, integrating AI as an operating system, and hiring non-family, institutional talent. Discover the four strategic imperatives—from navigating the $124 trillion succession crisis to adopting new governance frameworks—that are driving this era of Family Office Professionalisation in 2026.
Venture Investor Interviews
Targeting the Untouchable: The High-Stakes Race to Outsmart ‘Invisible’ Tumors
Percheron Therapeutics is developing the drug HMBD-002 to target the VISTA protein, aiming to make previously “invisible” cancers visible to the immune system. The company is preparing for its critical Phase 2 human trials in 2026 after successful Phase 1 results showed tumor shrinkage.
Australia’s Trillion-Dollar Defence Tech Boom: A Call to Action for Founders
The global defence technology landscape is no longer a niche for the select few. For Australian founders, it represents a monumental, yet frequently underestimated, investment opportunity. Fuelled by escalating geopolitical tensions and a fundamental re-prioritisation of global spending, this sector is experiencing an unprecedented tailwind. According to Steve Baxter, Lead Investor at Beaten Zone Venture […]
Cryptos New Frontier: Institutionalisation, Real-World Assets, and the End of Wild West Investing
The cryptocurrency landscape, once characterised by rapid cycles and speculative frenzy, is undergoing a profound transformation. As global institutions and high-net-worth individuals increasingly look to allocate capital to digital assets, the focus is shifting towards maturity, regulatory clarity, and the integration of blockchain technology with traditional finance. A recent at the Emergence Singapore 2025 panel […]
Moving to Venture Investing 3.0
The next ten years are going to be the most disruptive – and potentially the most profitable – in the history of venture capital. Learn what technologies and techniques you need to adopt in order to become a successful, next-generation private market investor from this keynote presentation by Hatcher+ Managing Partner John Sharp. Looking for […]
Investing in DeepTech for the Non-Technical Investors
When investing in DeepTech, understanding how to analyse the financials of a business can only take you so far. It is the investors who are able to conduct technological analysis that perform best. This is sometimes out of reach for investors with a non-technical background. If you’re a non-technical investor, watch this panel session as […]
What You Need to Know about ESG Investing
ESG stands for Environmental, Social and Governance. It makes up for factors that form part of any new or existing venture analysis. Investors are increasingly considering these factors as part of their analysis, especially on the institutional/VC side. Because of this, it is important to have a grasp on what exactly ESG entails, and how […]
Backed By Leading Investment Groups and Family Offices
